Telix Pharmaceuticals Ltd
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Telix Pharmaceuticals (TLX) shares surged 10% to $17.99 after FDA approval for its brain cancer imaging drug, Pixclara, with analysts seeing 37% upside. Domino's Pizza (DMP) shares rose 1% to $19.14 despite a 11.2% revenue drop and $134.2M loss, with brokers suggesting a hold. Wesfarmers (WES) shares fell 0.5% to $72.42 after a mixed FY26 report, with most analysts recommending a sell.
Telix Pharmaceuticals Ltd's (TLX) Group CFO, Darren Charlton Smith, acquired 2,071 ordinary shares at 9.656 AUD each under the company's employee share purchase plan, increasing his direct holdings to 13,992 shares.
Smith Darren Charlton (Group Chief Financial Officer) purchased 2,071 shares of Telix Pharmaceuticals Ltd (TLX) at $9.66 on 2026-09-07.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning TLX (Telix Pharmaceuticals Ltd). Coverage has skewed bullish: 7 bullish, 1 neutral, and 0 bearish.
Recent TLX coverage spans regulation, financial news and insider activity.
In the last 30 days, TLX insiders filed 1 SEC Form 4 transaction — 1 purchase ($20K) and no sales. The most active reporter was Smith Darren Charlton, Group Chief Financial Officer, with 1 filing.
Positive regulatory approval likely to boost Telix's revenue and market share in oncology imaging.
Small insider purchase likely has minimal price impact but signals confidence from CFO.
Small insider purchase signals confidence but limited material impact.
The approval validates Telix's product and opens a previously unavailable market segment.
Positive regulatory approval likely boosts Telix's revenue prospects and market perception.
AlphAI scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Telix Pharmaceuticals (TLX) shares surged 10% to $17.99 after FDA approval for its brain cancer imaging drug, Pixclara, with analysts seeing 37% upside. Domino's Pizza (DMP) shares rose 1% to $19.14 despite a 11.2% revenue drop and $134.2M loss, with brokers suggesting a hold. Wesfarmers (WES) shares fell 0.5% to $72.42 after a mixed FY26 report, with most analysts recommending a sell.
3 min readTelix Pharmaceuticals Ltd's (TLX) Group CFO, Darren Charlton Smith, acquired 2,071 ordinary shares at 9.656 AUD each under the company's employee share purchase plan, increasing his direct holdings to 13,992 shares.
1 min readSmith Darren Charlton (Group Chief Financial Officer) purchased 2,071 shares of Telix Pharmaceuticals Ltd (TLX) at $9.66 on 2026-09-07.
1 min readTelix Pharmaceuticals (TLX) announced FDA approval for Pixclara, a PET imaging drug for glioma. Pixclara is the first FDA-approved FET-PET imaging drug in the U.S. and is indicated for adults and pediatric patients. The approval may expand U.S. access to FET-PET imaging and support diagnosis and treatment planning. TLX stock closed at $11.29 on Friday and is up 8.95% in pre-market trading.
2 min readThe ASX 200 was flat at lunchtime on Monday. Telix Pharmaceuticals (TLX) shares rose 4% after the FDA approved its PET imaging drug for glioma brain cancer. Other movers: Cleanaway (CWY) +4%, FleetPartners (FPR) +10%, REA Group (REA) in focus after ACCC contract changes. Oil prices surged above $107 due to Middle East tensions and a likely Fed rate hike.
2 min readTelix Pharmaceuticals' stock rose 12% after the FDA approved its Pixclara drug for brain cancer imaging. The company reported H1 2026 revenue of $477M, up 22% YoY, with adjusted EBITDA increasing 146% and gross margin at 55%.
1 min readTelix Pharmaceuticals announced that the US FDA approved its new drug application for a brain cancer imaging drug. The company's stock has seen a 45.71% increase year-to-date, with a recent 4.08% rise. The approval may impact investor sentiment and trading activity.
1 min readTelix Pharmaceuticals' stock hit a 52-week high of $12.48, up 27.76% over the past year and 60% in six months. The company reported 33% revenue growth and strong first-half 2026 results, including 22% revenue increase and 146% EBITDA surge. H.C. Wainwright reiterated a Buy rating with a $20.00 price target, citing clinical trial progress and financial performance.
2 min readCSL, Ansell, and Ramsay led the ASX healthcare sector's strong August performance, with gains of 40%, 23.2%, and 16.2% respectively. The sector's total return index rose 44.1% from its June low, outperforming the broader market. Analysts are cautiously optimistic about FY27, but concerns remain about valuation and sustained growth.
2 min readTelix Pharmaceuticals (TLX) stock rose 5.2% in pre-market trading after completing patient enrollment in its Phase 3 BiPASS study for prostate cancer detection. The FDA aligned on an NDA pathway, and H.C. Wainwright reiterated a Buy rating with a $20.00 price target. The company reported strong H1 2026 financials, including 22% revenue growth and 146% EBITDA increase.
2 min read
